Details of the Drug Combination

General Information of Drug Combination (ID: DCQOW40)

Drug Combination Name
Alvespimycin hydrochloride Sapanisertib
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs Alvespimycin hydrochloride   DM6KU93 Sapanisertib   DMYZFNH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 10.969
Bliss Independence Score: 12.948
Loewe Additivity Score: 5.839
LHighest Single Agent (HSA) Score: 6.143

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Alvespimycin hydrochloride
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [2]
Refractory hematologic malignancy 2A85.5 Phase 1 [2]
Alvespimycin hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Sapanisertib
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Sapanisertib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN mammalian target of rapamycin (mTOR) TT7HQAF MTOR_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
DD2 DC2UGCJ DD2 Investigative [6]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
4 Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
5 Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.